The global DNA repair drugs market size is calculated at USD 9.36 billion in 2025 and is forecasted to reach around USD 30.28 billion by 2034, accelerating at a CAGR of 13.98% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: DNA Repair Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. DNA Repair Drugs Market, by Drug Type
8.1.1 PARP Inhibitors
8.1.1.1. Market Revenue and Forecast
8.1.2. ATM Kinase Inhibitors
8.1.2.1. Market Revenue and Forecast
8.1.3. ATR Inhibitors
8.1.3.1. Market Revenue and Forecast
8.1.4. DNA-PK Inhibitors
8.1.4.1. Market Revenue and Forecast
8.1.5. BER Inhibitors
8.1.5.1. Market Revenue and Forecast
8.1.6. NER Inhibitors
8.1.6.1. Market Revenue and Forecast
8.1.7. Mismatch Repair (MMR) Inhibitors
8.1.7.1. Market Revenue and Forecast
8.1.8. Homologous Recombination (HR) Inhibitors
8.1.8.1. Market Revenue and Forecast
8.1.9. Non-Homologous End Joining (NHEJ) Inhibitors
8.1.9.1. Market Revenue and Forecast
9.1. DNA Repair Drugs Market, by Application Type
9.1.1. Cancer Therapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Genetic Disorders
9.1.2.1. Market Revenue and Forecast
9.1.3. Neurodegenerative Diseases
9.1.3.1. Market Revenue and Forecast
9.1.4. Immune Deficiencies
9.1.4.1. Market Revenue and Forecast
9.1.5. Rare Genetic Syndromes
9.1.5.1. Market Revenue and Forecast
10.1. DNA Repair Drugs Market, by Distribution Channel
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast
10.1.4. Specialty Clinics
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type
11.1.2. Market Revenue and Forecast, by Application Type
11.1.3. Market Revenue and Forecast, by Distribution Channel
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type
11.1.4.2. Market Revenue and Forecast, by Application Type
11.1.4.3. Market Revenue and Forecast, by Distribution Channel
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type
11.1.5.2. Market Revenue and Forecast, by Application Type
11.1.5.3. Market Revenue and Forecast, by Distribution Channel
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type
11.2.2. Market Revenue and Forecast, by Application Type
11.2.3. Market Revenue and Forecast, by Distribution Channel
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type
11.2.4.2. Market Revenue and Forecast, by Application Type
11.2.4.3. Market Revenue and Forecast, by Distribution Channel
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type
11.2.5.2. Market Revenue and Forecast, by Application Type
11.2.5.3. Market Revenue and Forecast, by Distribution Channel
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type
11.2.6.2. Market Revenue and Forecast, by Application Type
11.2.6.3. Market Revenue and Forecast, by Distribution Channel
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type
11.2.7.2. Market Revenue and Forecast, by Application Type
11.2.7.3. Market Revenue and Forecast, by Distribution Channel
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type
11.3.2. Market Revenue and Forecast, by Application Type
11.3.3. Market Revenue and Forecast, by Distribution Channel
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type
11.3.4.2. Market Revenue and Forecast, by Application Type
11.3.4.3. Market Revenue and Forecast, by Distribution Channel
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type
11.3.5.2. Market Revenue and Forecast, by Application Type
11.3.5.3. Market Revenue and Forecast, by Distribution Channel
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type
11.3.6.2. Market Revenue and Forecast, by Application Type
11.3.6.3. Market Revenue and Forecast, by Distribution Channel
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type
11.3.7.2. Market Revenue and Forecast, by Application Type
11.3.7.3. Market Revenue and Forecast, by Distribution Channel
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type
11.4.2. Market Revenue and Forecast, by Application Type
11.4.3. Market Revenue and Forecast, by Distribution Channel
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type
11.4.4.2. Market Revenue and Forecast, by Application Type
11.4.4.3. Market Revenue and Forecast, by Distribution Channel
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type
11.4.5.2. Market Revenue and Forecast, by Application Type
11.4.5.3. Market Revenue and Forecast, by Distribution Channel
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type
11.4.6.2. Market Revenue and Forecast, by Application Type
11.4.6.3. Market Revenue and Forecast, by Distribution Channel
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type
11.4.7.2. Market Revenue and Forecast, by Application Type
11.4.7.3. Market Revenue and Forecast, by Distribution Channel
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type
11.5.2. Market Revenue and Forecast, by Application Type
11.5.3. Market Revenue and Forecast, by Distribution Channel
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type
11.5.4.2. Market Revenue and Forecast, by Application Type
11.5.4.3. Market Revenue and Forecast, by Distribution Channel
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type
11.5.5.2. Market Revenue and Forecast, by Application Type
11.5.5.3. Market Revenue and Forecast, by Distribution Channel
12.1. Abbvie Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Amgen Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbott
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Astrazeneca Plc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer Ag
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bristol-Myers Squibb Co.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Eli Lilly And Co.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. F. Hoffmann-La Roche Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Gilead Sciences Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gsk Plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample